ATE288496T1 - Gentherapie mit hilfe von schaf-adenoviralen vektoren - Google Patents
Gentherapie mit hilfe von schaf-adenoviralen vektorenInfo
- Publication number
- ATE288496T1 ATE288496T1 AT96926972T AT96926972T ATE288496T1 AT E288496 T1 ATE288496 T1 AT E288496T1 AT 96926972 T AT96926972 T AT 96926972T AT 96926972 T AT96926972 T AT 96926972T AT E288496 T1 ATE288496 T1 AT E288496T1
- Authority
- AT
- Austria
- Prior art keywords
- cell
- pct
- nucleic acid
- acid sequence
- gene therapy
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 2
- 241001494479 Pecora Species 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 3
- 210000005260 human cell Anatomy 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 abstract 1
- 241001503524 Ovine adenovirus Species 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN4776A AUPN477695A0 (en) | 1995-08-14 | 1995-08-14 | Gene therapy |
| PCT/AU1996/000518 WO1997006826A1 (en) | 1995-08-14 | 1996-08-14 | Gene therapy using ovine adenoviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE288496T1 true ATE288496T1 (de) | 2005-02-15 |
Family
ID=3789107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96926972T ATE288496T1 (de) | 1995-08-14 | 1996-08-14 | Gentherapie mit hilfe von schaf-adenoviralen vektoren |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6020172A (de) |
| EP (1) | EP0851769B1 (de) |
| JP (1) | JP4733795B2 (de) |
| AT (1) | ATE288496T1 (de) |
| AU (2) | AUPN477695A0 (de) |
| CA (1) | CA2229631C (de) |
| DE (1) | DE69634300T2 (de) |
| ES (1) | ES2237772T3 (de) |
| NZ (1) | NZ315295A (de) |
| WO (1) | WO1997006826A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037712B2 (en) * | 1994-07-26 | 2006-05-02 | Commonwealth Scientific And Industrial Research Organisation | DNA encoding ovine adenovirus (OAV287) and its use as a viral vector |
| FR2723697B1 (fr) * | 1994-08-17 | 1996-09-20 | Rhone Poulenc Rorer Sa | Methode de traitement de la restenose par la therapie genique |
| US6455314B1 (en) | 1998-09-11 | 2002-09-24 | Genvec, Inc. | Alternatively targeted adenovirus |
| US6440944B2 (en) | 1998-10-16 | 2002-08-27 | Genvec, Inc. | Methods of administering adenoviral vectors |
| JP2002535997A (ja) * | 1999-02-02 | 2002-10-29 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 細胞の老化および細胞の最終分化の際に向上した発現を示す遺伝子、およびその使用 |
| CA2364492C (en) * | 1999-03-01 | 2014-08-19 | Commonwealth Scientific And Industrial Research Organisation | Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene |
| EP1198579A1 (de) * | 1999-08-06 | 2002-04-24 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Nicht-humaner adenoviraler vektor für den gentransfer, seine anwendung und seine herstellung |
| US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
| DE10006886A1 (de) * | 2000-02-16 | 2001-08-23 | Hepavec Ag Fuer Gentherapie | Nichthumaner helferabhängiger Virusvektor |
| AU2001261650A1 (en) * | 2000-05-15 | 2001-11-26 | Geron Corporation | Ovine tissue for xenotransplantation |
| AU2001265154A1 (en) * | 2000-05-31 | 2001-12-11 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| CA2410665C (en) * | 2000-05-31 | 2017-11-07 | University Of Saskatchewan | Modified bovine adenovirus having altered tropism |
| CA2469623C (en) | 2001-12-12 | 2012-05-29 | F H Faulding & Co Limited | Composition for the preservation of viruses |
| AU2003241268A1 (en) * | 2002-02-05 | 2003-09-09 | Cornell Research Foundation, Inc. | Adenoviral vector with replication-dependent transgene expression |
| AUPS145602A0 (en) * | 2002-03-28 | 2002-05-09 | Commonwealth Scientific And Industrial Research Organisation | Composition and method for killing tumours |
| FR2842823A1 (fr) * | 2002-07-25 | 2004-01-30 | Inst Nat Sante Rech Med | Adenovirus modifies pour le ciblage des lymphocytes b |
| US20040225077A1 (en) | 2002-12-30 | 2004-11-11 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| US7342107B2 (en) * | 2004-05-27 | 2008-03-11 | Centocor, Inc. | Cynomolgus prostate specific antigen |
| AU2005329405A1 (en) * | 2004-06-15 | 2006-09-28 | Centocor, Inc. | Method for screening agents against human prostate disease |
| HUE046565T2 (hu) | 2009-03-02 | 2020-03-30 | Univ California | Tumorszelektív adenovírus E1A és E1B mutánsok |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| PL3198009T3 (pl) | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| AU2017336546C1 (en) | 2016-09-27 | 2025-05-29 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| KR102757384B1 (ko) | 2017-09-27 | 2025-01-20 | 에피센트알엑스, 인코포레이티드 | 면역조절 융합 단백질 |
| US12295976B2 (en) | 2018-03-28 | 2025-05-13 | Epicentrx, Inc. | Personalized cancer vaccines |
| JP7430395B2 (ja) | 2018-04-09 | 2024-02-13 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 複製特質が増強された腫瘍溶解性アデノウイルス組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2705361B1 (fr) * | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| CN1115414C (zh) * | 1993-07-13 | 2003-07-23 | 罗纳-布朗克罗莱尔股份有限公司 | 用于基因治疗的病毒载体 |
| US5552311A (en) * | 1993-09-14 | 1996-09-03 | University Of Alabama At Birmingham Research Foundation | Purine nucleoside phosphorylase gene therapy for human malignancy |
| US5820868A (en) * | 1993-12-09 | 1998-10-13 | Veterinary Infectious Disease Organization | Recombinant protein production in bovine adenovirus expression vector system |
| AU686844B2 (en) * | 1994-07-26 | 1998-02-12 | Commonwealth Scientific And Industrial Research Organisation | DNA encoding ovine adenovirus (OAV287) and its use as a viral vector |
| AUPM710194A0 (en) * | 1994-07-26 | 1994-08-18 | Commonwealth Scientific And Industrial Research Organisation | Virus vector |
| FR2724945B1 (fr) * | 1994-09-27 | 1996-12-27 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en therapie genique |
| FR2725726B1 (fr) * | 1994-10-17 | 1997-01-03 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en therapie genique |
| FR2726285B1 (fr) * | 1994-10-28 | 1996-11-29 | Centre Nat Rech Scient | Adenovirus depourvus de particules contaminantes viables, preparation et utilisation |
-
1995
- 1995-08-14 AU AUPN4776A patent/AUPN477695A0/en not_active Abandoned
-
1996
- 1996-08-14 US US09/011,525 patent/US6020172A/en not_active Expired - Lifetime
- 1996-08-14 ES ES96926972T patent/ES2237772T3/es not_active Expired - Lifetime
- 1996-08-14 DE DE69634300T patent/DE69634300T2/de not_active Expired - Lifetime
- 1996-08-14 EP EP96926972A patent/EP0851769B1/de not_active Expired - Lifetime
- 1996-08-14 JP JP50875597A patent/JP4733795B2/ja not_active Expired - Fee Related
- 1996-08-14 AT AT96926972T patent/ATE288496T1/de not_active IP Right Cessation
- 1996-08-14 NZ NZ315295A patent/NZ315295A/en unknown
- 1996-08-14 CA CA2229631A patent/CA2229631C/en not_active Expired - Fee Related
- 1996-08-14 AU AU66966/96A patent/AU708870B2/en not_active Ceased
- 1996-08-14 WO PCT/AU1996/000518 patent/WO1997006826A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU708870B2 (en) | 1999-08-12 |
| DE69634300T2 (de) | 2005-12-22 |
| JPH11511139A (ja) | 1999-09-28 |
| ES2237772T3 (es) | 2005-08-01 |
| EP0851769A1 (de) | 1998-07-08 |
| EP0851769A4 (de) | 1999-01-07 |
| WO1997006826A1 (en) | 1997-02-27 |
| CA2229631A1 (en) | 1997-02-27 |
| DE69634300D1 (de) | 2005-03-10 |
| CA2229631C (en) | 2011-05-24 |
| NZ315295A (en) | 1999-09-29 |
| EP0851769B1 (de) | 2005-02-02 |
| AUPN477695A0 (en) | 1995-09-07 |
| JP4733795B2 (ja) | 2011-07-27 |
| US6020172A (en) | 2000-02-01 |
| AU6696696A (en) | 1997-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69634300D1 (de) | Gentherapie mit hilfe von schaf-adenoviralen vektoren | |
| EP0710288A4 (de) | Adenovirale vektoren für die behandlung der hämophilie | |
| CY1106513T1 (el) | Λεντινοϊικο τριπλο dna και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dna | |
| AP1678A (en) | Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems. | |
| DE69731611D1 (de) | Eine Zusammensetzung enthaltend eine Detergenz und einen ein Tumorsuppressorgen kodierenden, adenoviralen Vektor | |
| DE69535703D1 (de) | Aav-vermittelte überbringung von dna in zellen des nervensystems | |
| Dhar et al. | Nucleotide sequence of the DNA replication origin for human papovavirus BKV: sequence and structural homology with SV40 | |
| DK0724642T3 (da) | Nukleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis | |
| ATE382694T1 (de) | Vektoren und methoden zum gentransfer in zellen | |
| DK0797678T3 (da) | Hybrid adenovirus-AAV-virus og fremgangsmåder til anvendelse af dette | |
| GB2325003B (en) | Rectroviral vectors | |
| ZA942778B (en) | Recombinant viruses, and their preparation and use in gene therapy. | |
| ATE403736T1 (de) | Onkolytische adenovirale vektoren | |
| ATE237694T1 (de) | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt | |
| CA2311643A1 (en) | Compositions and methods for inducing gene expression | |
| ATE345819T1 (de) | Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung | |
| FI973309A0 (fi) | Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi | |
| ATE475713T1 (de) | Trans-lentivirales vektor system | |
| DK1045901T3 (da) | Ribozymale nucleinsyrer, der spalter CCR5 eller CXCR4 | |
| DE60132443D1 (de) | In lebenden zielzellen | |
| WO1994013812A3 (en) | Novel entomopoxvirus genes, proteins and methods of use thereof | |
| FI971275A7 (fi) | Inaktivoidun IVa2-geenin käsittävät epätäydelliset yhdistelmä-DNA-tekn iset adenovirukset | |
| ATE377087T1 (de) | Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors | |
| BR9815496A (pt) | Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório | |
| AUPM710194A0 (en) | Virus vector |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |